OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Nivolumab+AVD in Advanced-Stage Classic Hodgkin’s Lymphoma
Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 15, pp. 1379-1389
Closed Access | Times Cited: 32
Alex F. Herrera, Michael LeBlanc, Sharon M. Castellino, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 15, pp. 1379-1389
Closed Access | Times Cited: 32
Showing 26-50 of 32 citing articles:
Pathobiological Features and Therapeutic Opportunities Linked to TNF Family Member Expression in Classic Hodgkin Lymphoma
Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone
Cancers (2024) Vol. 16, Iss. 23, pp. 4070-4070
Open Access | Times Cited: 2
Mohamed Nazem Alibrahim, Annunziata Gloghini, Antonino Carbone
Cancers (2024) Vol. 16, Iss. 23, pp. 4070-4070
Open Access | Times Cited: 2
Classic Hodgkin Lymphoma: the LYSA Pragmatic Guidelines
Cédric Rossi, Guillaume Manson, Amira Marouf, et al.
European Journal of Cancer (2024) Vol. 213, pp. 115073-115073
Open Access | Times Cited: 1
Cédric Rossi, Guillaume Manson, Amira Marouf, et al.
European Journal of Cancer (2024) Vol. 213, pp. 115073-115073
Open Access | Times Cited: 1
Rising to the Top: How Immune-Checkpoint Inhibitors are Changing the Landscape of Treatment for Classic Hodgkin Lymphoma
Ryan C. Lynch, Michael S. Binkley
Seminars in Radiation Oncology (2024) Vol. 35, Iss. 1, pp. 40-46
Closed Access | Times Cited: 1
Ryan C. Lynch, Michael S. Binkley
Seminars in Radiation Oncology (2024) Vol. 35, Iss. 1, pp. 40-46
Closed Access | Times Cited: 1
Cancer-specific innate and adaptive immune rewiring drives resistance to PD-1 blockade in classic Hodgkin lymphoma
Julia Paczkowska, Ming Tang, Kyle Wright, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Julia Paczkowska, Ming Tang, Kyle Wright, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Therapy for Hodgkin’s Lymphoma — Can It Get Any Better?
Jamés O. Armitage, Dan L. Longo
New England Journal of Medicine (2024) Vol. 391, Iss. 15, pp. 1452-1454
Closed Access
Jamés O. Armitage, Dan L. Longo
New England Journal of Medicine (2024) Vol. 391, Iss. 15, pp. 1452-1454
Closed Access
Hodgkin lymphoma therapy: minimising clinical and biological harms
Simonetta Viviani, Corrado Tarella
The Lancet Oncology (2024)
Closed Access
Simonetta Viviani, Corrado Tarella
The Lancet Oncology (2024)
Closed Access
Life after cancer matters: supporting 2.1 million survivors of adolescent and young adult cancer
AnnaLynn M. Williams, Michael Roth
JNCI Journal of the National Cancer Institute (2024)
Closed Access
AnnaLynn M. Williams, Michael Roth
JNCI Journal of the National Cancer Institute (2024)
Closed Access
Antibody-Based Immunotherapies for the Treatment of Hematologic Malignancies
Justyna Jureczek, Krzysztof Kałwak, Piotr Dzięgiel
Cancers (2024) Vol. 16, Iss. 24, pp. 4181-4181
Open Access
Justyna Jureczek, Krzysztof Kałwak, Piotr Dzięgiel
Cancers (2024) Vol. 16, Iss. 24, pp. 4181-4181
Open Access
Improved Overall Survival with Checkpoint Inhibition and Allogeneic Transplantation in Relapsed Hodgkin Lymphoma
Nadeem Tabbara, Marianna Zahurak, Cole Sterling, et al.
Blood Advances (2024)
Open Access
Nadeem Tabbara, Marianna Zahurak, Cole Sterling, et al.
Blood Advances (2024)
Open Access
